January 2026
Depression
What January 2026's 25 new studies found, synthesized from the papers below. All Depression research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Depression, major depressive disorder, MDD, depressive disorder, treatment-resistant depression, then ranked by relevance.
Research published in January 2026 indicates that psychedelic and glutamatergic treatments—particularly psilocybin, esketamine, and ketamine—show promising antidepressant effects, with psilocybin demonstrating large effect sizes and esketamine showing substantial real-world effectiveness, though one RCT found ketamine no better than placebo in inpatients. Evidence is mixed regarding durability and optimal protocols, and most studies are reviews, retrospective, or small, with limited long-term safety data.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| The Use of Psilocybin in the Treatment of Depressive Disorders: A Narrative Review 2026 | narrative review | Supports | Psilocybin-assisted therapy shows promising results with higher therapeutic efficacy compared to conventional treatments for depression, offering hope for a modern approach with sustained effects and minimal adverse effects. | |
| 5-Methoxy-N,N-Dimethyltryptamine: Functional Safety Pharmacology and Video-EEG Assessment of a Short-Acting Serotonergic Psychedelic in Beagle Canines. 2026 | preclinical animal study | 11 | Supports | Intranasal administration of 5-MeO-DMT did not induce seizures or epileptiform activity in a canine model sensitive to serotonergic drug-induced seizures. |
| Multimodal rapid anti-depression: Esketamine combined with dexmedetomidine patient-controlled sleep for treatment-resistant depression - A retrospective study. 2026 | retrospective cohort | 233 | Supports | Multimodal therapy combining esketamine and dexmedetomidine patient-controlled sleep was associated with sustained improvements in depressive symptoms and sleep quality over 6 months, with an acceptable safety profile. |
| Single-dose DMT reverses anhedonia and cognitive deficits via restoration of neurogenesis in a stress-induced depression model. 2026 | preclinical animal study | Supports | A single dose of DMT reversed depressive-like behavior and cognitive deficits in stressed male mice and enhanced adult-born granule cell integration, outperforming fluoxetine in most domains. | |
| Prophylactic esketamine to reduce postpartum depression in primiparae: A multicentre, double-blind, randomised clinical trial. 2026 | randomized controlled trial | 322 | Supports | Peri-operative adjunctive administration of esketamine significantly reduced the total incidence of postpartum depression within 3 months postpartum compared to placebo in primiparae without prenatal depression. |
| Combining Intranasal Esketamine and Electroconvulsive Therapy in Severe Treatment‑Resistant Depression: A Case Series. 2026 | case series | 4 | Supports | Combined ECT and esketamine was associated with sustained symptom improvement and wider ECT spacing in four patients with treatment-resistant depression. |
| Mindful Yoga Therapy For Elderly Depression: Community-Based Nonpharmacological Approach 2026 | review | Supports | Mindful yoga therapy offers a non-pharmacological approach to improving mental health in older adults with depression. | |
| The impact of mindfulness-based stress reduction therapy on individuals with autism spectrum disorder and their caregivers: A systematic review. 2026 | systematic review | 13 | Supports | MBSR shows potential for improving anxiety and depression in adults with ASD and for alleviating stress and emotional distress in ASD caregivers, but evidence is limited. |
| Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies. 2026 | systematic review and meta-analysis | 9 | Supports | Intranasal esketamine was associated with substantial symptom reduction and increasing remission rates over time in real-world treatment of treatment-resistant depression. |
| Modulating tonic NMDA receptor currents: mechanistic insights into ketamine, esketamine, and dextromethorphan for major depressive disorder and implications for the discovery and development of investigational agents. 2026 | review | Supports | Selective dampening of NR2C/D-mediated tonic NMDA receptor currents underlies the rapid and sustained antidepressant effects of ketamine, esketamine, and dextromethorphan in treatment-resistant depression. | |
| Ketamine in the treatment of bipolar depression 2026 | review | 6 | Supports | Ketamine appears to be an alternative treatment for bipolar depression when first- and second-line medications are not effective. |
| PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION 2026 | narrative review | Supports | Psilocybin-assisted therapy demonstrates rapid, robust, and sustained antidepressant effects with high response and remission rates, often after one or two sessions, and a generally favorable safety profile. | |
| Astroglia and depression: A Gliocentric perspective from rodent models to therapeutic insights. 2026 | review | Supports | Astroglial dysfunction is a fundamental component of the pathophysiology of depression, and both standard and atypical antidepressants exert therapeutic effects at least partially by restoring astroglial homeostasis. | |
| The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidence 2026 | review | Supports | Psilocybin produces substantial reductions in depressive symptoms with large effect sizes and durable benefits lasting up to one year, and has a favorable safety profile with mild, transient adverse events. | |
| Psychedelics in psychiatric treatment: a literature review 2026 | literature review | Supports | Psychedelic-assisted therapies, including psilocybin, LSD, MDMA, and ketamine, show therapeutic efficacy for major depressive disorder, PTSD, substance use disorders, and anxiety disorders, with associated risks requiring clinical oversight. | |
| The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression 2026 | systematic review and meta-analysis | 7 | Supports | Psilocybin at 25 mg per dosing session is effective for reducing depressive severity in treatment-resistant depression. |
| Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis 2026 | systematic review and meta-analysis | 522 | Supports | Psilocybin-assisted therapy has a large and significant antidepressant effect, with larger effects linked to bodyweight-adjusted doses and extended therapy sessions. |
| Serial ketamine infusions not effective as adjunctive care for depression 2026 | randomized controlled trial | No effect | Up to eight infusions of ketamine were not more effective than a psychoactive placebo (midazolam) in reducing depressive symptoms or improving cognition and quality of life in patients receiving inpatient treatment for depression. | |
| Long-term effectiveness and side-effects of intranasal esketamine in treatment-resistant depression: real-world, single-arm study of over 100 sessions. 2026 | retrospective, single-arm, pre-post study | 20 | Supports | Intranasal esketamine, administered over an average of 129 sessions (2.5 years), led to significant reductions in depression and anxiety scores, with 85% of patients improving in depressive severity and 25% achieving remission, while side effects were generally mild and transient. |
| Time matters for metas: a systematic review and meta-analysis of ect vs ketamine for depression incorporating time. 2026 | systematic review and meta-analysis | 731 | Supports | ECT produced a faster rate of improvement in depressive symptoms than ketamine, with a predicted moderate efficacy advantage after four weeks. |
| Symptom trajectories and clinical outcomes of intravenous ketamine in treatment-resistant depression: A real-world study using group-based trajectory modeling. 2026 | retrospective chart review | 209 | Mixed | IV ketamine produced statistically significant but modest symptom improvement, with substantial heterogeneity in treatment trajectories and no significant difference in response rates between four and six infusions. |
| Does psilocybin help with mental health conditions? 2026 | review/statement | Supports | Psilocybin therapy shows potential benefits for depression and substance use disorders, though long-term safety and efficacy require further study. | |
| Efficacy of Oral Ketamine in Patients with Depression and Suicidality: A Retrospective Study. 2026 | retrospective cross-sectional study | 41 | Supports | Oral ketamine therapy was associated with significant reductions in depressive symptoms and suicidal ideation after three sessions. |
| Bridging ancient substances and modern psychiatry: the role of classic psychedelics in depression treatment. 2026 | narrative review | Supports | Classic psychedelics produce antidepressant effects comparable to traditional treatments, likely through 5-HT2A receptor binding and promotion of neuroplasticity. | |
| Progress, potential and pitfalls of ketamine as a treatment for depression 2026 | review | Supports | Evidence supports the antidepressant effects of intravenous ketamine and intranasal esketamine, with adequate safety data for long-term treatment, though challenges remain regarding bias and cost. |
Psilocybin-assisted therapy shows promising results with higher therapeutic efficacy compared to conventional treatments for depression, offering hope for a modern approach with sustained effects and minimal adverse effects.
narrative review
Intranasal administration of 5-MeO-DMT did not induce seizures or epileptiform activity in a canine model sensitive to serotonergic drug-induced seizures.
preclinical animal study Sample size: 11
Multimodal therapy combining esketamine and dexmedetomidine patient-controlled sleep was associated with sustained improvements in depressive symptoms and sleep quality over 6 months, with an acceptable safety profile.
retrospective cohort Sample size: 233
A single dose of DMT reversed depressive-like behavior and cognitive deficits in stressed male mice and enhanced adult-born granule cell integration, outperforming fluoxetine in most domains.
preclinical animal study
Peri-operative adjunctive administration of esketamine significantly reduced the total incidence of postpartum depression within 3 months postpartum compared to placebo in primiparae without prenatal depression.
randomized controlled trial Sample size: 322
Combined ECT and esketamine was associated with sustained symptom improvement and wider ECT spacing in four patients with treatment-resistant depression.
case series Sample size: 4
Mindful yoga therapy offers a non-pharmacological approach to improving mental health in older adults with depression.
review
MBSR shows potential for improving anxiety and depression in adults with ASD and for alleviating stress and emotional distress in ASD caregivers, but evidence is limited.
systematic review Sample size: 13
Intranasal esketamine was associated with substantial symptom reduction and increasing remission rates over time in real-world treatment of treatment-resistant depression.
systematic review and meta-analysis Sample size: 9
Selective dampening of NR2C/D-mediated tonic NMDA receptor currents underlies the rapid and sustained antidepressant effects of ketamine, esketamine, and dextromethorphan in treatment-resistant depression.
review
Ketamine appears to be an alternative treatment for bipolar depression when first- and second-line medications are not effective.
review Sample size: 6
Psilocybin-assisted therapy demonstrates rapid, robust, and sustained antidepressant effects with high response and remission rates, often after one or two sessions, and a generally favorable safety profile.
narrative review
Astroglial dysfunction is a fundamental component of the pathophysiology of depression, and both standard and atypical antidepressants exert therapeutic effects at least partially by restoring astroglial homeostasis.
review
Psilocybin produces substantial reductions in depressive symptoms with large effect sizes and durable benefits lasting up to one year, and has a favorable safety profile with mild, transient adverse events.
review
Psychedelic-assisted therapies, including psilocybin, LSD, MDMA, and ketamine, show therapeutic efficacy for major depressive disorder, PTSD, substance use disorders, and anxiety disorders, with associated risks requiring clinical oversight.
literature review
Psilocybin at 25 mg per dosing session is effective for reducing depressive severity in treatment-resistant depression.
systematic review and meta-analysis Sample size: 7
Psilocybin-assisted therapy has a large and significant antidepressant effect, with larger effects linked to bodyweight-adjusted doses and extended therapy sessions.
systematic review and meta-analysis Sample size: 522
Up to eight infusions of ketamine were not more effective than a psychoactive placebo (midazolam) in reducing depressive symptoms or improving cognition and quality of life in patients receiving inpatient treatment for depression.
randomized controlled trial
Intranasal esketamine, administered over an average of 129 sessions (2.5 years), led to significant reductions in depression and anxiety scores, with 85% of patients improving in depressive severity and 25% achieving remission, while side effects were generally mild and transient.
retrospective, single-arm, pre-post study Sample size: 20
ECT produced a faster rate of improvement in depressive symptoms than ketamine, with a predicted moderate efficacy advantage after four weeks.
systematic review and meta-analysis Sample size: 731
IV ketamine produced statistically significant but modest symptom improvement, with substantial heterogeneity in treatment trajectories and no significant difference in response rates between four and six infusions.
retrospective chart review Sample size: 209
Psilocybin therapy shows potential benefits for depression and substance use disorders, though long-term safety and efficacy require further study.
review/statement
Oral ketamine therapy was associated with significant reductions in depressive symptoms and suicidal ideation after three sessions.
retrospective cross-sectional study Sample size: 41
Classic psychedelics produce antidepressant effects comparable to traditional treatments, likely through 5-HT2A receptor binding and promotion of neuroplasticity.
narrative review
Evidence supports the antidepressant effects of intravenous ketamine and intranasal esketamine, with adequate safety data for long-term treatment, though challenges remain regarding bias and cost.
review
Points of agreement
- Psilocybin-assisted therapy consistently shows large, rapid, and sustained antidepressant effects across reviews and meta-analyses.
- Esketamine, both intranasal and intravenous, is associated with significant symptom reduction and increasing remission over time in real-world and trial settings.
- Ketamine and esketamine are generally well-tolerated with mild, transient adverse events, though long-term monitoring for urinary symptoms is needed.
- Mechanistic reviews converge on 5-HT2A receptor activation and neuroplasticity for psychedelics, and NMDA receptor modulation for ketamine/esketamine.
Conflicts
- One RCT found ketamine no more effective than midazolam in inpatients, conflicting with positive findings from other ketamine studies.
- ECT was found to produce faster improvement than ketamine, while other studies highlight ketamine's rapid effects, suggesting comparative efficacy varies.
- Some reviews report durable benefits lasting up to a year, while others note limited long-term data and call for further study.
Gaps
- Long-term durability of antidepressant effects beyond 6 months to a year is not well established.
- Most evidence comes from reviews, retrospective studies, and small samples; more large, blinded RCTs are needed.
- Optimal dosing and treatment protocols (e.g., number of sessions, bodyweight-adjusted dosing) remain unclear.
- Safety data for long-term use, especially for urinary symptoms with esketamine and potential adverse effects, require further monitoring.
- Real-world effectiveness in diverse populations and settings is understudied.